Page 6 - Fusion Antibodies Blog

Clarity Press Release

Fusion Antibodies and Clarity Pharmaceuticals sign agreement for Fsn0503 anti-Cathepsin antibody

Fusion Antibodies Ltd, an antibody drug and cell line development CRO focused on the treatment of serious disease, has signed an exclusive licensing agreement with Clarity Pharmaceuticals Ltd. (Sydney, Australia) to further develop Fusion’s Cathepsin S specific antibody for the treatment of a range of cancers.

Fusion Antibodies featured in EBR Magazine

Fusion Antibodies featured in EBR Magazine

Fusion Antibodies Nominated for Irish Times InterTradeIreland Innovation Award

Fusion Antibodies Nominated for Irish Times InterTradeIreland Innovation Award

Fusion Antibodies Develop High Expression Level Stable Cell Line for ISCA Diagnostics

Fusion Antibodies Develop High Expression Level Stable Cell Line for ISCA Diagnostics

Humanized Antibody for Invasive Pulmonary Aspergillosis: Fusion Antibodies and ISCA Diagnostic collaboration

Humanized Antibody for Invasive Pulmonary Aspergillosis: Fusion Antibodies and ISCA Diagnostic collaboration

Fusion Antibodies ltd and Chiome Bioscience Inc collaboration in Chicken Antibody Sequences Humanization

Fusion Antibodies ltd and Chiome Bioscience Inc collaboration in Chicken Antibody Sequences Humanization

Antibodies Alma Mater – Queen’s University

Antibodies Alma Mater – Queen’s University

Antibodies inhibit Cathepsin S to stop metastasis

Antibodies inhibit Cathepsin S to stop metastasis – news from Memorial Sloan Kettering research team

Fusion Antibodies helps students examine a career in Stratified Medicine

Fusion Antibodies helps students examine a career in Stratified Medicine

Fusion Antibodies to Humanize Avipero’s integrin antibody platform

Fusion Antibodies to Humanize Avipero’s integrin antibody platform

< Back 1 2 3 4 5 6 7 8 9 10 Next >